Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05157191
Other study ID # Pro00110056
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 6, 2022
Est. completion date October 27, 2023

Study information

Verified date December 2023
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to < 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the 7 days following each vaccination using either identical web-based or paper diaries, depending on study participant preference. At Duke University, Cincinnati's Children Hospital, and Kaiser Permanente Northern California, serum samples will be collected for optional assessment of antibody titers to COVID-19. Each participant who opts in will have baseline (within 3 days of vaccination) serologies obtained and immunogenicity assessment at 28 (+7) days after each dose. All participants will be followed for 180 days after dose 2 for serious adverse events and adverse events of special interest.


Recruitment information / eligibility

Status Completed
Enrollment 299
Est. completion date October 27, 2023
Est. primary completion date May 25, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 15 Years
Eligibility Inclusion Criteria: 1. Children = 5 years to < 16 years of age 2. Receiving first dose or a booster dose of a U.S authorized or approved and recommended COVID-19 vaccine per standard of care 3. Parent/legal authorized representative (LAR) willing to provide written informed consent per local IRB requirements 4. Participant willing to provide assent per local IRB requirements 5. Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls 6. English or Spanish literate. Exclusion Criteria: 1. Current or planned participation in any clinical trial with an investigational product during the study period.* - Per protocol, co-enrollment in observational or behavioral intervention studies are permitted at any time. An investigational product or behavioral intervention permitted at any time. An investigational product may be permitted for therapy of an illness condition that occurs during the study period (e.g., COVID-19 illness) 2. Any condition, which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives. 3. Anyone who is a relative of any research study personnel or is an employee supervised by study staff.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational
Observational

Locations

Country Name City State
United States Centers for Disease Control and Prevention Atlanta Georgia
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Duke University Durham North Carolina
United States Columbia University New York New York
United States Kaiser Permanente Northern California Oakland California

Sponsors (5)

Lead Sponsor Collaborator
Duke University Centers for Disease Control and Prevention, Children's Hospital Medical Center, Cincinnati, Columbia University, Kaiser Permanente

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with defined local or systemic reactogenicity events after each dose of COVID-19 vaccine Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe Up to 7 days post-vaccination
Primary Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after each dose of COVID-19 vaccine Tables summarizing each severe (Grade 3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Primary Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after each dose of COVID-19 vaccine Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Primary Number of participants with an unsolicited adverse events after each dose of COVID-19 vaccine The number and percent and descriptions of unsolicited adverse events observed Up to 7 days post-vaccination
Primary Number of participants with an adverse event of special interest The number and percent of individuals with an adverse event of special interest after dose 2 of COVID-19 vaccine Up to 29 days post-vaccination
Primary The number and percent of participants with at least one serious adverse event after dose 2 of COVID-19 vaccine The number and percent of serious adverse events observed and description of each event Up to 29 days post-vaccination
Secondary Number of participants with defined local or systemic reactogenicity events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe Up to 7 days post-vaccination
Secondary Number of participants with defined local or systemic reactogenicity events after receiving each dose of COVID-19 vaccine without other vaccines Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe Up to 7 days post-vaccination
Secondary Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after other routinely recommended vaccines with each dose of COVID-19 vaccine Tables summarizing each moderate to severe (Grade 2-3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Secondary Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after receiving COVID-19 vaccine without receiving other vaccines Tables summarizing each severe (Grade 3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Secondary Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Secondary Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after receiving COVID-19 vaccine without receiving other vaccines Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event Up to 7 days post-vaccination
Secondary Number of participants with an unsolicited adverse events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine The number and percent and descriptions of unsolicited adverse events observed Up to 7 days post-vaccination
Secondary Number of participants with an unsolicited adverse events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine without receiving other vaccines The number and percent and descriptions of unsolicited adverse events observed Up to 7 days post-vaccination
Secondary Number of participants with an adverse event of special interest who received other routinely recommended vaccines with each dose of COVID-19 vaccine The number and percent of individuals who had at least one adverse event of special interest Up to 29 days post-vaccination
Secondary Number of participants with an adverse event of special interest who received other routinely recommended vaccines with each dose of COVID-19 vaccine without receiving other vaccines The number and percent of individuals who had at least one adverse event of special interest Up to 29 days post-vaccination
Secondary The number and percent of participants with at least one serious adverse event who received other routinely recommended vaccines after dose 2 of COVID-19 vaccine The number and percent of serious adverse events observed and description of each event Up to 29 days post-vaccination
Secondary The number and percent of participants with at least one serious adverse event who received other routinely recommended vaccines after dose 2 of COVID-19 vaccine without receiving other vaccines The number and percent of serious adverse events observed and description of each event Up to 29 days post-vaccination
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care